[go: up one dir, main page]

PE20000441A1 - Mesilato de n-(3-etinilfenilamino)-6,7-bis(2-metoxietoxi)-4-quinazolinamina anhidro y monohidratado - Google Patents

Mesilato de n-(3-etinilfenilamino)-6,7-bis(2-metoxietoxi)-4-quinazolinamina anhidro y monohidratado

Info

Publication number
PE20000441A1
PE20000441A1 PE1999000356A PE00035699A PE20000441A1 PE 20000441 A1 PE20000441 A1 PE 20000441A1 PE 1999000356 A PE1999000356 A PE 1999000356A PE 00035699 A PE00035699 A PE 00035699A PE 20000441 A1 PE20000441 A1 PE 20000441A1
Authority
PE
Peru
Prior art keywords
polymorph
methoxyetoxy
quinazolinamine
mesilate
bis
Prior art date
Application number
PE1999000356A
Other languages
English (en)
Inventor
Timothy Norris
Ravi Mysore Shanker
Dinos Paul Santafianos
Douglas John Meldrum Allen
Jeffrey William Raggon
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of PE20000441A1 publication Critical patent/PE20000441A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

SE REFIERE A FORMAS ANHIDRAS E HIDRATADAS DEL MESILATO DE N-(3-ETINILFENIL)-6,7-BIS-(2-METOXIETOXI)-4-QUINAZOLINAMINA, LA FORMA ANHIDRA (POLIMORFO A) SE CARACTERIZA POR SU PATRON DE DIFRACCCION DE RAYOS X. LA FORMA ANHIDRA (POLIMORFO B) SE CARACTERIZA POR SU PATRON DE DIFRACCION DE RAYOS X. LA FORMA ANHIDRA (POLIMORFO C) CARACTERIZADO POR SU PATRON DE DIFRACCION DE RAYOS X. TAMBIEN SE REFIERE A COMPOSICIONES QUE COMPRENDEN INHIBIDORES MITOTICOS, AGENTES ALQUILANTES, ANTI-METABOLITOS, ANTIBIOTICOS INTERCALANTES, INHIBIDORES DEL FACTOR DE CRECIMIENTO, INHIBIDORES DEL CICLO CELULAR, INHIBIDORES DE LA TOPOISOMERASA, MODIFICADORES DE LA RESPUESTA BIOLOGICA, ANTI-HORMONA, ANTI-ANDROGENOS. EL COMPUESTO ES UN INHIBIDOR DE erbB DE TIROSINQUINASA ONCOGENICAS Y PROTOONCOGENICAS LAS QUE PUEDEN SER UTILES EN EL TRATAMIENTO DE UNA ALTERACION HIPERPROLIFERATIVA TAL COMO CANCER DE CEREBRO, PULMON, CELULA ESCAMOSA, VEJIGA, GASTRICO, PANCREATICO, MAMA, CABEZA, GARGANTA, RENAL, RINON, OVARICO, ESOFAGICO, GINECOLOGICO, TIROIDES
PE1999000356A 1998-04-29 1999-04-29 Mesilato de n-(3-etinilfenilamino)-6,7-bis(2-metoxietoxi)-4-quinazolinamina anhidro y monohidratado PE20000441A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8344198P 1998-04-29 1998-04-29

Publications (1)

Publication Number Publication Date
PE20000441A1 true PE20000441A1 (es) 2000-05-23

Family

ID=22178359

Family Applications (1)

Application Number Title Priority Date Filing Date
PE1999000356A PE20000441A1 (es) 1998-04-29 1999-04-29 Mesilato de n-(3-etinilfenilamino)-6,7-bis(2-metoxietoxi)-4-quinazolinamina anhidro y monohidratado

Country Status (41)

Country Link
EP (1) EP1076652B1 (es)
JP (1) JP4652569B2 (es)
KR (1) KR100668412B1 (es)
CN (2) CN1298396A (es)
AP (1) AP1252A (es)
AR (1) AR018201A1 (es)
AT (1) ATE295839T1 (es)
AU (1) AU759691C (es)
BR (1) BR9910025A (es)
CA (1) CA2330447C (es)
CO (1) CO5060467A1 (es)
CZ (1) CZ298230B6 (es)
DE (1) DE69925366T2 (es)
DZ (1) DZ2777A1 (es)
EA (1) EA002836B1 (es)
EG (1) EG24000A (es)
ES (1) ES2238825T3 (es)
GT (1) GT199900063A (es)
HN (1) HN1999000057A (es)
HU (1) HU227569B1 (es)
ID (1) ID27198A (es)
IL (1) IL139172A0 (es)
MA (1) MA26624A1 (es)
ME (1) MEP42008A (es)
MX (1) MXPA00010610A (es)
MY (1) MY136033A (es)
NO (1) NO317301B1 (es)
NZ (1) NZ508154A (es)
OA (1) OA11769A (es)
PA (1) PA8471001A1 (es)
PE (1) PE20000441A1 (es)
PL (1) PL196940B1 (es)
RS (1) RS50081B (es)
SA (1) SA99200216B1 (es)
TN (1) TNSN99079A1 (es)
TR (1) TR200003166T2 (es)
TW (1) TWI248437B (es)
UA (1) UA60363C2 (es)
UY (1) UY26099A1 (es)
WO (1) WO1999055683A1 (es)
ZA (1) ZA992972B (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6706721B1 (en) 1998-04-29 2004-03-16 Osi Pharmaceuticals, Inc. N-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate anhydrate and monohydrate
RS49836B (sr) 1999-03-31 2008-08-07 Pfizer Products Inc., Postupci i intermedijeri za dobijanje anti-kancernih jedinjenja
UA74803C2 (uk) * 1999-11-11 2006-02-15 Осі Фармасьютікалз, Інк. Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування
US7087613B2 (en) 1999-11-11 2006-08-08 Osi Pharmaceuticals, Inc. Treating abnormal cell growth with a stable polymorph of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride
UA73993C2 (uk) 2000-06-06 2005-10-17 Астразенека Аб Хіназолінові похідні для лікування пухлин та фармацевтична композиція
WO2003000188A2 (en) 2001-06-21 2003-01-03 Ariad Pharmaceuticals, Inc. Novel quinazolines and uses thereof
US7078409B2 (en) 2002-03-28 2006-07-18 Beta Pharma, Inc. Fused quinazoline derivatives useful as tyrosine kinase inhibitors
GB0223854D0 (en) * 2002-10-12 2002-11-20 Astrazeneca Ab Therapeutic treatment
US7148231B2 (en) * 2003-02-17 2006-12-12 Hoffmann-La Roche Inc. [6,7-Bis(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)amine hydrochloride polymorph
NZ543234A (en) 2003-05-30 2009-04-30 Astrazeneca Uk Ltd Marker genes and uses thereof to identify cancer patients that will respond to erbb tyrosine kinase inhibitors
AU2004247418B2 (en) 2003-06-10 2009-11-05 F. Hoffmann-La Roche Ag 1.3.4-triaza-phenalene and 1,3,4,6-tetraazaphenalene derivatives
GB0403744D0 (en) 2004-02-20 2004-03-24 Astrazeneca Ab Chemical process
CA2565721C (en) 2004-05-06 2015-10-06 Bioresponse, L.L.C. Diindolymethane formulations for the treatment of leiomyomas
DE602005026328D1 (de) 2004-12-30 2011-03-24 Bioresponse Llc Verwendung von diindolylmethan-verwandten indolen zur behandlung und prävention von erkrankungen im zusammenhang mit dem respiratory syncytial virus
EP2054393A1 (en) 2006-07-28 2009-05-06 Synthon B.V. Crystalline erlotinib
BRPI0717753B1 (pt) 2006-10-27 2022-04-12 Bioresponse, Llc Uso de uma composição compreendendo 50-250 mg de um ou mais indóis relacionados com dim e um ou mais agentes anti-protozoários, e, composição
KR101441930B1 (ko) * 2007-04-04 2014-09-19 시플라 리미티드 에르로티닙 및 그의 약학적으로 허용가능한 염의 제조방법
WO2009007984A2 (en) 2007-07-11 2009-01-15 Hetero Drugs Limited An improved process for erlotinib hydrochloride
EP2218713A1 (en) 2007-08-17 2010-08-18 Hetero Drugs Limited Erlotinib hydrochloride polymorph Form A substantially free of polymorph Form B
KR101132937B1 (ko) * 2008-10-01 2012-04-06 주식회사종근당 Ｎ-(3-에티닐페닐)-6,7-비스(2-메톡시에톡시)-4-퀴나졸린아민 납실레이트 염
CN102438995B (zh) 2009-03-26 2014-12-17 兰贝克赛实验室有限公司 厄洛替尼或其药学上可接受的盐的制备工艺
WO2011068404A2 (en) 2009-12-02 2011-06-09 Ultimorphix Technologies B.V. Administration of n-(3-ethynylphenylamino)-6,7-bis(2- methoxyethoxy)-4-quinazolinamine mesylate salt by inhalation
DE202010006543U1 (de) 2010-05-07 2010-09-09 Ratiopharm Gmbh Erlotinibresinat
HU230483B1 (hu) 2011-10-10 2016-07-28 Egis Gyógyszergyár Nyrt. Erlotinib sók
NZ630289A (en) 2012-09-04 2016-08-26 Shilpa Medicare Ltd Crystalline erlotinib hydrochloride process

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ243082A (en) * 1991-06-28 1995-02-24 Ici Plc 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
JP2994165B2 (ja) * 1992-06-26 1999-12-27 ゼネカ・リミテッド キナゾリン誘導体、その製造法および該キナゾリン誘導体を含有する抗癌作用を得るための医薬調剤
GB9323290D0 (en) * 1992-12-10 1994-01-05 Zeneca Ltd Quinazoline derivatives
EP0817775B1 (en) * 1995-03-30 2001-09-12 Pfizer Inc. Quinazoline derivatives
US5747498A (en) * 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines

Also Published As

Publication number Publication date
CN101219999A (zh) 2008-07-16
MY136033A (en) 2008-07-31
DE69925366T2 (de) 2006-03-09
DZ2777A1 (fr) 2003-12-01
MXPA00010610A (es) 2002-07-02
ZA992972B (en) 2000-10-30
UY26099A1 (es) 2001-12-28
MEP42008A (en) 2011-02-10
EA200001112A1 (ru) 2001-04-23
AU759691C (en) 2004-04-29
CN1298396A (zh) 2001-06-06
EG24000A (en) 2008-03-19
EA002836B1 (ru) 2002-10-31
SA99200216B1 (ar) 2006-06-04
HUP0101818A3 (en) 2002-05-28
HN1999000057A (es) 1999-09-29
EP1076652B1 (en) 2005-05-18
IL139172A0 (en) 2001-11-25
NO317301B1 (no) 2004-10-04
KR20010078710A (ko) 2001-08-21
CO5060467A1 (es) 2001-07-30
MA26624A1 (fr) 2004-12-20
HUP0101818A1 (hu) 2002-03-28
ATE295839T1 (de) 2005-06-15
BR9910025A (pt) 2000-12-26
AU2850999A (en) 1999-11-16
CZ20003974A3 (en) 2001-05-16
ES2238825T3 (es) 2005-09-01
CA2330447A1 (en) 1999-11-04
AU759691B2 (en) 2003-04-17
JP2002513009A (ja) 2002-05-08
DE69925366D1 (de) 2005-06-23
AP9901523A0 (en) 1999-06-30
PL343766A1 (en) 2001-09-10
TWI248437B (en) 2006-02-01
AP1252A (en) 2004-02-25
JP4652569B2 (ja) 2011-03-16
UA60363C2 (uk) 2003-10-15
OA11769A (en) 2005-07-25
GT199900063A (es) 2000-10-20
HK1037180A1 (en) 2002-02-01
PA8471001A1 (es) 2000-09-29
NZ508154A (en) 2003-07-25
TNSN99079A1 (fr) 2005-11-10
WO1999055683A1 (en) 1999-11-04
CZ298230B6 (cs) 2007-08-01
YU66100A (sh) 2003-07-07
AR018201A1 (es) 2001-10-31
ID27198A (id) 2001-03-08
EP1076652A1 (en) 2001-02-21
TR200003166T2 (tr) 2001-02-21
CA2330447C (en) 2009-06-30
RS50081B (sr) 2009-01-22
HU227569B1 (en) 2011-08-29
KR100668412B1 (ko) 2007-01-12
NO20005453L (no) 2000-12-20
NO20005453D0 (no) 2000-10-27
PL196940B1 (pl) 2008-02-29

Similar Documents

Publication Publication Date Title
PE20000441A1 (es) Mesilato de n-(3-etinilfenilamino)-6,7-bis(2-metoxietoxi)-4-quinazolinamina anhidro y monohidratado
IS7319A (is) Fjölgervingar klópídógrelvetnissúlfats
SG196855A1 (en) Substituted pyrazolo[1,5-a]pyrimidine compounds as trk kinase inhibitors
DE602004017196D1 (de) Kondensierte azabicyclische verbindungen, die den vanilloidrezeptorsubtyp 1 (vr1)- rezeptor inhibieren
DE60141706D1 (de) Verbindungen mit fungizider wirkung und verfahren zur ihrer herstellung und verwendung
UY27127A1 (es) Derivados de la urea como antagonistas de integrin alfa-4
EP2022834A4 (en) NITROGENIC ALLOY AND THEIR USE FOR THE PREPARATION OF PHOSPHORUS
GEP20084528B (en) 5,7-DIAMINOPYRAZOLO [4,3-d] PYRIMIDINES WITH PDE-5 INHIBITING ACTIVITY
AR068086A2 (es) Polimorfos del compuesto triazolo (4,5-d) pirimidina , una mezcla , proceso para su preparacion , composicion farmaceutica y uso de estos compuestos para la fabricacion de medicamentos
GT200300087A (es) 2-(2,6-diclorofenil)-diarilimidazoles
MY142018A (en) Thiophene derivatives as chk 1 inihibitors
DOP2002000447A (es) 1-alquil o 1-cicloalquiltriazolo [4,3-a] quinazolin-5 onas como inhibidores de fosfodiesterasas
TW200640859A (en) Substituted bis aryl and heteroaryl compounds as selective 5HT2A antagonists
ECSP088156A (es) Compuestos farmacéuticos novedosos
GB0222056D0 (en) Process for the manufacture of organic compounds
DOP2009000073A (es) Inhibidores de cinasa que catalizan la transferencia de fosforilo y/o que enlazan nucleótidos atp/gtp.
ZA200405239B (en) Process for the manufacture of organic compounds
IL174469A0 (en) Rearranged pentanols, a method for the production thereof, and their use as antiphlogistics
CO5700731A2 (es) Polimorfos cristalinos de un ligando receptor de cxc-quimiocina
GB0204129D0 (en) Process for the manufacture of organic compounds
MX2023009562A (es) Formas de monohidrato y cristalinas de 6-[(3s,4s)-4-metil-1-(pirim idin-2-ilmetil)pirrolidin-3-il]-3-tetrahidropiran-4-il-7h-imidazo [1,5-a]pirazin-8-ona.
MX2008013724A (es) Proceso para la preparacion de formas polimorficas de hidrogeno sulfato clopidrogel.
TW200745137A (en) Thieno[2,3-b]pyridine-5-carbonitriles as protein kinase inhibitors
CR7512A (es) Procedimiento para preparar derivados de 6-alquiliden-penem
NZ589108A (en) Imidazo [2,1-b] quinazolin-2-one derivatives and their use as platelet anti-aggregative agents

Legal Events

Date Code Title Description
FC Refusal